News & Updates

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.

In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.

A nationally representative study led by researchers from the University of Hong Kong and Xi’an Jiaotong University Health Science Centre, China, has shown that a five-test (ie, serum HBsAg/HBsAb/HBeAg/HBeAb/HBcAb) universal screening strategy in people aged 18–70 years is the most cost-effective hepatitis B virus (HBV) screening option in China.

Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.